Literature DB >> 12761096

Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection.

María Colmenares1, Peter E Kima, Erika Samoff, Lynn Soong, Diane McMahon-Pratt.   

Abstract

Previous studies have demonstrated that protection against New World leishmaniasis caused by Leishmania amazonensis can be elicited by immunization with the developmentally regulated Leishmania amastigote antigen, P-8. In this study, several independent experimental approaches were employed to investigate the protective immunological mechanisms involved. T-cell subset depletion experiments clearly indicate that elicitation of CD8(+) (as well as CD4(+)) effector responses is required for protection. Further, mice lacking beta(2)-microglobulin (and hence deficient in major histocompatibility complex class I antigen presentation) were not able to control a challenge infection after vaccination, indicating an essential protective role for CD8(+) T effector responses. Analysis of the events ongoing at the cutaneous site of infection indicated a changing cellular dynamic involved in protection. Early postinfection in protectively vaccinated mice, a predominance of CD8(+) T cells, secreting gamma interferon (IFN-gamma) and expressing perforin, was observed at the site of infection; subsequently, activated CD4(+) T cells producing IFN-gamma were primarily found. As protection correlated with the ratio of total IFN-gamma-producing cells (CD4(+) and CD8(+) T cells) to macrophages found at the site of infection, a role for IFN-gamma was evident; in addition, vaccination of IFN-gamma-deficient mice failed to provide protection. To further assess the effector mechanisms that mediate protection, mice deficient in perforin synthesis were examined. Perforin-deficient mice vaccinated with the P-8 antigen were unable to control infection. Thus, the elicitation of CD8(+) T cell effector mechanisms (perforin, IFN-gamma) are clearly required in the protective immune response against L. amazonensis infection in vaccinated mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761096      PMCID: PMC155724          DOI: 10.1128/IAI.71.6.3172-3182.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  68 in total

1.  Role of T cell subsets during the recall of immunologic memory to Leishmania major.

Authors:  I Müller
Journal:  Eur J Immunol       Date:  1992-12       Impact factor: 5.532

2.  Enhanced antibody and cytokine responses to influenza viral antigens in perforin-deficient mice.

Authors:  S Sambhara; I Switzer; A Kurichh; R Miranda; L Urbanczyk; O James; B Underdown; M Klein; D Burt
Journal:  Cell Immunol       Date:  1998-07-10       Impact factor: 4.868

3.  The resolution of lesions induced by Leishmania major in mice requires a functional Fas (APO-1, CD95) pathway of cytotoxicity.

Authors:  F Conceição-Silva; M Hahne; M Schröter; J Louis; J Tschopp
Journal:  Eur J Immunol       Date:  1998-01       Impact factor: 5.532

4.  Mice defective in Fas are highly susceptible to Leishmania major infection despite elevated IL-12 synthesis, strong Th1 responses, and enhanced nitric oxide production.

Authors:  F P Huang; D Xu; E O Esfandiari; W Sands; X Q Wei; F Y Liew
Journal:  J Immunol       Date:  1998-05-01       Impact factor: 5.422

5.  Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes.

Authors:  A Müllbacher; P Waring; R Tha Hla; T Tran; S Chin; T Stehle; C Museteanu; M M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

6.  Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis.

Authors:  H W Murray; S Delph-Etienne
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

7.  Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells.

Authors:  I Müller; T Pedrazzini; P Kropf; J Louis; G Milon
Journal:  Int Immunol       Date:  1991-06       Impact factor: 4.823

8.  Resistance to murine cutaneous leishmaniasis is mediated by TH1 cells, but disease-promoting CD4+ cells are different from TH2 cells.

Authors:  H Moll; M Röllinghoff
Journal:  Eur J Immunol       Date:  1990-09       Impact factor: 5.532

9.  An antimicrobial activity of cytolytic T cells mediated by granulysin.

Authors:  S Stenger; D A Hanson; R Teitelbaum; P Dewan; K R Niazi; C J Froelich; T Ganz; S Thoma-Uszynski; A Melián; C Bogdan; S A Porcelli; B R Bloom; A M Krensky; R L Modlin
Journal:  Science       Date:  1998-10-02       Impact factor: 47.728

10.  The interaction between CD8+ cytotoxic T cells and Leishmania-infected macrophages.

Authors:  L E Smith; M Rodrigues; D G Russell
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

View more
  42 in total

1.  Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis.

Authors:  E Carrillo; S Ahmed; K Goldsmith-Pestana; J Nieto; Y Osorio; B Travi; J Moreno; D McMahon-Pratt
Journal:  Vaccine       Date:  2006-11-10       Impact factor: 3.641

2.  Live Attenuated Leishmania donovani Centrin Gene-Deleted Parasites Induce IL-23-Dependent IL-17-Protective Immune Response against Visceral Leishmaniasis in a Murine Model.

Authors:  Antara Banerjee; Parna Bhattacharya; Pradeep K Dagur; Subir Karmakar; Nevien Ismail; Amritanshu B Joshi; Adovi D Akue; Mark KuKuruga; John Philip McCoy; Ranadhir Dey; Hira L Nakhasi
Journal:  J Immunol       Date:  2017-11-29       Impact factor: 5.422

3.  CD8+ T Cells Lack Local Signals To Produce IFN-γ in the Skin during Leishmania Infection.

Authors:  Fernanda O Novais; Andrea C Wong; Daniel O Villareal; Daniel P Beiting; Phillip Scott
Journal:  J Immunol       Date:  2018-01-24       Impact factor: 5.422

4.  The contribution of the Fas/FasL apoptotic pathway in ulcer formation during Leishmania major-induced cutaneous Leishmaniasis.

Authors:  Liv Eidsmo; Susanne Nylen; Ali Khamesipour; Mari-Anne Hedblad; Francesca Chiodi; Hannah Akuffo
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

5.  Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells.

Authors:  Sylvie Bertholet; Alain Debrabant; Farhat Afrin; Elisabeth Caler; Susana Mendez; Khaled S Tabbara; Yasmine Belkaid; David L Sacks
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Immunologic Markers of Protection in Leishmania (Viannia) braziliensis Infection: A 5-Year Cohort Study.

Authors:  Aline C Muniz; Olívia Bacellar; Ednaldo Lima Lago; Augusto M Carvalho; Pedro Paulo Carneiro; Luiz Henrique Guimarães; Paulo N Rocha; Lucas P Carvalho; Marshall Glesby; Edgar M Carvalho
Journal:  J Infect Dis       Date:  2016-05-18       Impact factor: 5.226

7.  Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.

Authors:  Blaise Dondji; Eszter Deak; Karen Goldsmith-Pestana; Eva Perez-Jimenez; Mariano Esteban; Sachiko Miyake; Takashi Yamamura; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2008-03       Impact factor: 5.532

8.  Immunological perspectives of leishmaniasis.

Authors:  Susanne Nylén; Shalini Gautam
Journal:  J Glob Infect Dis       Date:  2010-05

9.  Leishmania pifanoi proteoglycolipid complex P8 induces macrophage cytokine production through Toll-like receptor 4.

Authors:  Shanta M Whitaker; Maria Colmenares; Karen Goldsmith Pestana; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2008-02-25       Impact factor: 3.441

10.  Gamma interferon production, but not perforin-mediated cytolytic activity, of T cells is required for prevention of toxoplasmic encephalitis in BALB/c mice genetically resistant to the disease.

Authors:  Xisheng Wang; Hoil Kang; Takane Kikuchi; Yasuhiro Suzuki
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.